OrsoBio
Ryan Huss, MD, is a seasoned leader in clinical development and operations, currently serving as SVP at OrsoBio since February 2022, having previously held the role of VP at the same company. Prior experience includes Senior Director of Clinical Development at Gilead Sciences from 2019 to February 2022, where Ryan led global development efforts for non-alcoholic steatohepatitis (NASH). Clinical expertise encompasses roles as Director of Clinical Development at Santa Clara Valley Medical Center and Internal Medicine Physician. Additionally, Ryan contributed to biopharma strategy as Engagement Manager at McKinsey & Company. Educational credentials include a Bachelor's degree in Biology from Stanford University and an MD in Bioengineering from Stanford University School of Medicine.
This person is not in any teams
OrsoBio
OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat severe metabolic disorders, including type 2 diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism.